Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. (TVTX) has a notice of proposed sale of common stock filed under Rule 144 for officer Elizabeth Reed. The notice covers 39,576 shares of Travere common stock to be sold through Morgan Stanley Smith Barney, with an aggregate market value of $2,603,705.04 and based on 94,261,082 shares outstanding as of September 15, 2026. The shares consist of 37,500 shares underlying stock options expected to be exercised for cash on September 15, 2026 and 2,076 shares from performance stock units with a date of May 4, 2026.
Travere Therapeutics, Inc. (TVTX) received a notice that Eric Dube plans to sell shares of the company’s common stock under Rule 144. The notice covers up to 95,666 shares of common stock with an aggregate market value of $6,293,866.14 as of September 15, 2026.
The planned sale is to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ market and is tied to the exercise of stock options for cash on September 15, 2026.
Travere Therapeutics, Inc. (TVTX) discloses that officer Peter Heerma has filed a notice to sell up to 102,190 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with sales expected to begin on or about September 15, 2026 on NASDAQ.
The shares relate to equity compensation awards, including 77,190 shares from stock options exercisable for cash, and shares underlying restricted stock units and performance stock units that vested over the period from October 1, 2021 through January 31, 2025.
Travere Therapeutics, Inc. (TVTX) received a notice that officer William Rote plans to sell up to 96,198 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $6,328,866.42. The planned sales are expected to occur on or about September 15, 2026 on NASDAQ. As context, 94,261,082 shares of common stock were outstanding, a baseline figure, not the amount being sold.
The shares to be sold were acquired via several equity compensation arrangements: 78,650 shares from the exercise of stock options, 9,128 shares from an employee stock purchase plan, and a total of 8,420 shares from restricted and performance stock units that vested between February 13, 2018 and January 31, 2024.
Travere Therapeutics, Inc. (TVTX) has an officer, Jula Inrig, filing a notice of proposed sale of common stock under Rule 144. The notice lists common shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ around September 15, 2026, with a quantity of 44,674 shares and an aggregate market value of $2,939,102.46, while the company reports 94,261,082 common shares outstanding.
The securities to be sold were acquired from the issuer through equity compensation, including stock options exercised for 32,395 shares on September 15, 2026, restricted stock units vesting for 7,662 shares on January 1, 2023, and performance stock units vesting for 4,617 shares on February 10, 2025. The notice states that the securities to be sold were acquired upon vesting of restricted stock units during the period from January 1, 2023 through January 31, 2025.
Travere Therapeutics, Inc. (TVTX) director Jeffrey A. Meckler reported option exercises and related share sales on September 10, 2026. He exercised stock options for 10,000 shares at $17.44 and 10,000 shares at $26.52, receiving a total of 20,000 shares of common stock.
On the same date, he sold 20,000 shares of common stock in market transactions, split into four tranches of 1,700; 1,200; 14,000; and 3,100 shares at weighted average prices of $65.3917, $66.15, $67.4634, and $68.088, respectively. These sales were made under a Rule 10b5-1(c) trading plan adopted on June 11, 2026, and involved shares underlying fully vested options expiring in 2027 and 2028.
Travere Therapeutics, Inc. (TVTX) has a notice under Rule 144 indicating that director Jeffrey Meckler plans to sell up to 20,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC after a cash exercise of stock options on September 10, 2026.
The filing lists an aggregate market value of $1,324,400 for the 20,000 shares, with sales expected to occur on or after September 10, 2026 on the NASDAQ market.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Financial Officer, Christopher R. Cline, sold 642 shares of common stock on September 2, 2026 at $66.37 per share. According to the company’s disclosure, this sale was a mandatory “sell to cover” transaction to satisfy tax withholding on vested restricted stock units and was not a discretionary trade by the officer, and no Rule 10b5-1 trading plan is reported.
Travere Therapeutics, Inc. (TVTX) director Gary A. Lyons reported an exercise-and-sell sequence over August 17–18, 2026. He exercised stock options for 10,000 shares of common stock at an exercise price of $17.44 per share (options fully vested and expiring May 17, 2027), acquiring 10,000 shares. He then sold 10,000 shares of common stock in multiple tranches at weighted-average prices ranging from about $62.53 to $64.16 per share. All sales were made pursuant to a written trading plan adopted on May 18, 2026 under Rule 10b5-1(c).
Travere Therapeutics, Inc. (TVTX) received a notice that director Gary Lyons plans to sell company common stock under Rule 144. The planned transaction involves 5,000 shares of common stock, with a stated aggregate market value of $317,650.00, through Morgan Stanley Smith Barney on or about 08/18/2026. The shares are to be sold in connection with the exercise of stock options for cash. The notice also lists a prior 10b5-1 sale of 5,000 shares on 08/17/2026 for total proceeds of $315,985.50.